Quadrant Capital Group’s 2seventy bio TSVT Stock Holding History

Quadrant Capital Group’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13	Closed	–	–	2740
2022 Q1	$0	Sell	13 -14	-52%	-$237	﹤0.01%	2698
2021 Q4	$1K	Buy	+27	New	+$842	﹤0.01%	2413

Other funds holding TSVT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Quadrant Capital Group's TSVT Position: Q2 2022 in Review

Quadrant Capital Group sold out of 2seventy bio (TSVT) in Q2 2022, closing a stake of 13 shares.

Quadrant Capital Group first reported a position in TSVT in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 132 funds tracked by Wall St. Rank hold TSVT as of Q2 2022.

Quadrant Capital Group reported no remaining 2seventy bio position as of Q2 2022 after selling out during the quarter.
Quadrant Capital Group sold 13 2seventy bio shares in Q2 2022.
Quadrant Capital Group first reported a position in 2seventy bio in Q4 2021 and held it in 2 quarters.
Quadrant Capital Group's 2seventy bio position peaked at $1K in Q4 2021.
132 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.